647 results on '"Emery, Sean"'
Search Results
2. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
3. The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk : A SMART and START Combined Analysis
4. In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus
5. Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial
6. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study
7. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects
8. Technical rehearsal of tritium operation at JET
9. ART in HIV-positive persons with low pre-treatment viremia: results from the START trial
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
11. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial
12. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial
13. Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
14. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015
15. Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm3: Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial
16. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
17. ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial
18. Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
19. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis
20. Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial
21. Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells
22. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
23. The search for an HIV cure: tackling latent infection
24. Autophagy Inhibition for Chemosensitization and Radiosensitization in Cancer: Do the Preclinical Data Support This Therapeutic Strategy?
25. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
26. Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study
27. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection
28. Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4⁺ T-Cell Response: A Randomized Controlled Trial
29. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
30. Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment—Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study
31. Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1—Infected Individuals Commencing cART? A Randomized, Controlled Study
32. Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial
33. Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction
34. Disease Progression and Fatal Outcomes in HIV-Infected Patients during Interruption of Antiretroviral Treatment [with Reply to Cooper et al.]
35. In vivo, Nucleoside Reverse-Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA
36. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes
37. Interleukin-2 in Clinical Trials: Other Factors to Be Considered [with Reply]
38. Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease
39. A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4⁺ Cell Counts ⩾350/mm³
40. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels
41. Outpatient Continuous Intravenous Interleukin-2 or Subcutaneous, Polyethylene Glycol-Modified Interleukin-2 in Human Immunodeficiency Virus-Infected Patients: A Randomized, Controlled, Multicenter Study
42. Autophagy, cell death and sustained senescence arrest in B16/F10 melanoma cells and HCT-116 colon carcinoma cells in response to the novel microtubule poison, JG-03-14
43. Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy
44. Drug Companies Have a Duty to Continue Treatment
45. Role of Interleukin-2 in Patients with HIV Infection
46. Comparison of central and local HIV-1 RNA quantification from two international clinical trials
47. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
48. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies
49. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection
50. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.